Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 1, 2005, Pages 66-77

  Shou, Magang ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cytochrome P450; Drug clearance; Drug drug interaction; Drug metabolizing enzyme; Enzyme inhibition; Enzyme kinetics; Half life of drug elimination; Hepatocytes; Liver microsomes; Mechanism based enzyme inhibition; Oral bioavailability; Pharmacokinetics

Indexed keywords

ALFENTANIL; ALPRAZOLAM; AMITRIPTYLINE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; DIAZEPAM; DICLOFENAC; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; IBUPROFEN; ITRACONAZOLE; KETOCONAZOLE; LORNOXICAM; MEVINOLIN; MIDAZOLAM; PARACETAMOL; PHENACETIN; PHENPROCOUMON; QUINIDINE; SULFAMETHIZOLE; TERFENADINE; TOLBUTAMIDE; TRIAZOLAM; WARFARIN;

AREA UNDER THE CURVE; BIOTRANSFORMATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; LIVER CLEARANCE; PREDICTION; REVIEW;

ALGORITHMS; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 12244295474     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. Rodrigues AD (Ed): Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences. Marcel Dekker, New York, NY, USA (2002) 116. Provides a comprehensive overview of DDIs from both preclinical and clinical perspectives.
2. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (Eds): Metabolic Drug Interactions. Lippincott Willams and Wilkins, Philadelphia, PA, USA (2000). Describes DDIs from their fundamental concept to clinical implication.
3. Obach RS: Drug-drug interactions: An important negative attribute in drugs. Drugs Today (2003) 39(5):301-338. Provides a comprehensive overview of DDIs at the level of DMEs and transporters. Each DME is discussed to assess its potential for DDIs, based on previously published reports.
4. Obach RS: The prediction of human clearance from hepatic microsomal metabolism data. Curr Opin Drug Discovery Dev (2001) 4(1):36-44. Describes the approaches used to predict clearance in humans from hepatic microsomal data.
5. Lin JH: Sense and nonsense in the prediction of drug-drug interactions. Curr Drug Metab (2000) 1(4):305-331. Provides a comprehensive evaluation of DDIs using different approaches for their prediction, analyses and the potential problems involved in the prediction.
6. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y: Prediction of pharmacokinetic alterations caused by drug-drug interactions: Metabolic interaction in the liver. Pharmacol Rev (1998) 50(3):387-411. Provides a comprehensive overview of PK and DDI predictions in principles and models.
7. Greenblatt DJ, Von Moltke LL: Drug-drug interactions: Clinical perspective. In: Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences. Rodrigues AD (Ed), Marcel Dekker, New York, NY, USA (2002) 116:565-584. Provides an overview of DDIs from a clinical perspective. Examples of clinical cases are given based on the mechanism of DME inhibition.
8. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan JM: Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Brit J Clin Pharmacol (2004) 57(5):592-599.
9. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI: Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin Pharmacol Ther (1998) 64(3):237-247.
10. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD: The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther (1998) 64(4):369-377.
11. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, Hall SD: The contribution of intestinal and hepatic CYP3A4 to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther (1998) 64(2):133-143.
12. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ: The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther (1995) 58(1):15-19.
13. Floren LC, Bekersky I, Benet LZ, Mekki Q, Dressler D, Lee JW, Roberts JP, Hert MF: Tacrolimus oral bioavailability doubles with coadminstration of ketoconazole. Clin Pharmacol Ther (1997) 62(1):41-49.
14. Varhe A, Olkkola KT, Neuvonen PJ: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 56(6 Pt 1):601-607.
15. Backman JT, Olkkola KT, Aranko K, Himberg J-J, Veuvonen PJ: Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol (1994) 37(3):221-225.
16. Smith DA: Induction and drug development. Eur J Pharm Sci (2000) 11(3):185-189.
17. Schuetz EG: Induction of cytochromes P450. Curr Drug Metab (2001) 2(2):139-147.
18. Lin JH, Lu AY: Interindividual variability in inhibition and induction of cytochrome P450 enzymes. Ann Rev Pharmacol Tox (2001) 41:535-567.
19. Yuan R, Madani S, Wei X-X, Reynolds K, Huang S-M: Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos (2002) 30(12):1311-1319. Highlights the FDA recommendations on probe substrates and inhibitors to individual CYPs.
20. Wang RW, Newton DJ, Liu N, Atkins WM, Lu AY: Human cytochrome P-450 3A4: In vitro drug-drug interaction patterns are substrate-dependent. Drug Metab Dispos (2000) 28(3):360-366.
21. Pang KS, Rowland M: Hepatic clearance of drugs. I. Theoretical considerations of a 'well-stirred' model and a 'parallel tube' model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm (1977) 5(6):625-653.
22. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Ranee DJ, Wastall P: The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther (1997) 283(1):46-58. Provides comprehensive evaluations of the prediction of human PKs using a pharmaceutical industry dataset.
23. Rowland M: Introducing pharmacokinetic and pharmacodynamic concepts. In: Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences. Rodrigues AD (Ed), Marcel Dekker, New York, NY, USA (2002) 116:1-31.
24. Lin JH, Pearson PG: Prediction of metabolic drug interactions: Quantitative or qualitative? In: Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences. Rodrigues AD (Ed), Marcel Dekker, New York, NY, USA (2002) 116:415-438. Discusses approaches that are commonly used to predict clearance from in vitro kinetic data.
25. Korzakwa KR: In vitro enzyme kinetics applied to drug-metabolizing enzymes. In: Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences. Rodrigues AD (Ed), Marcel Dekker, New York, NY, USA (2002) 116:33-54. Describes the concepts of typical and atypical enzyme kinetics and the approaches to generating kinetic parameters.
26. i and plasma protein binding measurements.
27. Venkatakrishnan K, von Moltke LL, Greenblatt DJ: Human drug metabolism and the cytochromes P450: Application and relevance of in vitro models. J Clin Pharmacol (2001) 41(11):1149-1179.
28. von Moltke LL, Greeblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI: In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol (1998) 55(2):113-122.
29. Mayhew BS, Jones DR, Hall SD: An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos (2000) 28(9):1031-1037.
30. Kanamitsu SI, Ito K, Sugiyama Y: Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmakinetics: Use of maximum unbound concentration of inhibitor at the inlet to the liver. Pharm Res (2000) 17(3):336-343.
31. Tucker GT, Houston JB, Huang SM: Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Clin Pharmacol Ther (2001) 70(2):103-114.
32. El-Sankary W, Gibson GG, Ayrton A, Plant N: Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos (2001) 29(11):1499-1504.
33. Rane A, Wilkinson GR, Shand DG: Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J Pharmacol Exp Ther (1977) 200(2):420-431.
34. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI: Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol (1999) 19(4):293-296.
35. Naritomi Y, Terashita S, Kagayama A, Sugiyama Y: Utility of hepatocytes in predicting drug metabolism: Comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab Dispos (2003) 31(5):580-588.
36. Obach RS: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos (1999) 27(11): 1350-1359.
37. Yang TJ, Shou M, Korzekwa K, Gonzalez FJ, Gelboin HV, Yang SK: Role of cDNA expressed human cytochromes P450 in the metabolism of diazepam. Biochem Pharmacol (1998) 55(6):889-896.
38. Davies B, Morris T: Physiological parameters in laboratory animals and humans. Pharm Res (1993) 10(7):1093-1095. Contains physiological values collected from both preclinical species and humans that can be used for scaling.
39. Wilkinson GR: Clearance approaches in pharmacology. Pharmacol Rev (1987)39(1):1-47.
40. Kalvass JC, Tess DA, Giragossian C, Linhares MC, Maurer TS: Influence of microsomal concentration on apparent intrinsic clearance: Implications for scaling in vitro data. Drug Metab Dispos (2001) 29(10):1332-1336.
41. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ: The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab Dispos (2002) 30(12):1497-1503.
42. Alvan G, Piafsky K, Lind M, von Bahr C: Effect of pentobarbital on the disposition of alprenolol. Clin Pharmacol Ther (1977) 22(3):316-321.
43. Jones DR, Hall SD: Mechanism-based inhibition of human cytochromes P450: In vitro kinetics and in vitro-in vivo correlation. In: Drug-Drug Interactions. Drugs and the Pharmaceutical Sciences. Rodrigues AD (Ed), Marcel Dekker, New York, NY, USA (2002) 116:387-413. Comprehensive review of mechanism-based inhibition, including basic concepts, approaches and examples for in vitro-in vivo prediction.
44. Shou M, Lin Y, Lu P, Tang C, Mei Q, Cui D, Tang W, Ngui JS, Lin C, Singh R, Wong B et al: Enzyme kinetics of cytochrome P450-mediated reactions. Curr Drug Metab (2001) 2(1):17-36. Describes the in vitro kinetic models and equations involved in different types of CYP inhibition.
45. Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH: Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metab Dispos (2003) 31(5):565-571.
46. Andersson, TB, Bredberg E, Ericsson H, Sjöberg H: An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab Dispos (2004) 32(7)1715-721.
47. i and dangers associated with high clearance drugs in general. J Pharm Pharm Sci (1999) 2(2):47-52.
48. Kohl C, Steinkellner M: Prediction of pharmacokinetic drug/drug interactions from in vitro data: Interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. Drug Metab Dispos (2000) 28(2):161-168.
49. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shatter RI: In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol (1994) 34(12):1222-1227.
50. 2 receptor antagonists in rats. Drug Metab Dispos (1998) 26(4):318-323.
51. Yamano K, Yamamoto K, Kotaki H, Sawada Y, Iga T: Quantitative predition of metabolic inhibition of midazolam by intraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos (1999) 27(3):395-402.
52. Yamano K, Yamamoto K, Kotaki H, Takedomi S, Matsuo H, Sawada Y, Iga T: Quantitative prediction of metabolic inhibition of midazolam by erythromycin, diltiazem, and verapamil in rats: Implication of concentrative uptake of inhibitors into liver. J Phamtacol Exp Ther (2000) 292(3):1118-1126.
53. Yamano K, Yamamoto K, Katashima M, Kotaki H, Takedomi S, Matsuo H, Ohtani H, Sawada Y, Iga T: Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution and metabolism data. Drug Metab Dispos (2001) 29(4 Pt 1):443-452.
54. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, Hall SD: Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther (1999) 290(3):1116-1125.